Cargando…

Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

Transporters can play a key role in the absorption, distribution, metabolism, and excretion of drugs. Understanding these contributions early in drug discovery allows for more accurate projection of the clinical pharmacokinetics. One method to assess the impact of transporters in vivo involves co‐do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rowbottom, Christopher, Pietrasiewics, Alicia, Tuczewycz, Taras, Grater, Richard, Qiu, Daniel, Kapadnis, Sudarshan, Trapa, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931226/ https://www.ncbi.nlm.nih.gov/pubmed/33660938 http://dx.doi.org/10.1002/prp2.740

Ejemplares similares

The P-glycoprotein Inhibitor GF120918 Modulates Ca(2+)-Dependent Processes and Lipid Metabolism in Toxoplasma Gondii
por: Bottova, Iveta, et al.
Publicado: (2010)

The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells
por: Traunecker, H C L, et al.
Publicado: (1999)

The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
por: Karbownik, Agnieszka, et al.
Publicado: (2019)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

[(11)C]Elacridar as a novel P-glycoprotein PET tracer, assessment of whole-body distribution and radiation dosimetry in humans
por: Bauer, Martin, et al.
Publicado: (2011)

Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
por: Lehne, G., et al.
Publicado: (1998)

Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
por: Gekeler, V., et al.
Publicado: (1996)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022)

Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
por: Kono, Yusuke, et al.
Publicado: (2021)

Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
por: Kusunoki, Nobuya, et al.
Publicado: (1998)

ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein
por: Rösch, Lisa, et al.
Publicado: (2022)

Generating Inhibitors of P-Glycoprotein: Where to, Now?
por: Crowley, Emily, et al.
Publicado: (2009)

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15
por: Uchiyama‐Kokubu, Noriko, et al.
Publicado: (2001)

Marine Natural Products with P-Glycoprotein Inhibitor Properties
por: Lopez, Dioxelis, et al.
Publicado: (2014)

Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia
por: Labbozzetta, Manuela, et al.
Publicado: (2023)

Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells †
por: Teodori, Elisabetta, et al.
Publicado: (2020)

Dual regulation of P-glycoprotein expression by Trichostatin A in cancer cell lines
por: Balaguer, Trinidad Mata, et al.
Publicado: (2012)

A PET microdosing study with the P-glycoprotein inhibitor tariquidar
por: Bauer, Martin, et al.
Publicado: (2012)

Inostamycin, an Inhibitor of P‐Glycoprotein Function, Interacts Specifically with Phosphatidylethanolamine
por: Kawada, Manabu, et al.
Publicado: (1995)

New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells
por: Braconi, Laura, et al.
Publicado: (2022)

Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors
por: Poongavanam, Vasanthanathan, et al.
Publicado: (2012)

Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors
por: Klepsch, Freya, et al.
Publicado: (2013)

New fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte cultures
por: Jaszczyszyn, Agata, et al.
Publicado: (2012)

Role of P-Glycoprotein Inhibitors in the Bioavailability Enhancement of Solid Dispersion of Darunavir
por: Rehman, Saleha, et al.
Publicado: (2017)

Effects of P-Glycoprotein and Its Inhibitors on Apoptosis in K562 Cells
por: Zu, Yaqiong, et al.
Publicado: (2014)

Multiclass Classifier for P-Glycoprotein Substrates, Inhibitors, and Non-Active Compounds
por: Mora Lagares, Liadys, et al.
Publicado: (2019)

P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors
por: Kopecka, Joanna, et al.
Publicado: (2016)

Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
por: Kopecka, Joanna, et al.
Publicado: (2020)

Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
por: Ruponen, Marika, et al.
Publicado: (2021)

Screening of Natural Compounds as P-Glycoprotein Inhibitors against Multidrug Resistance
por: Marques, Sérgio M., et al.
Publicado: (2021)

Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport
por: Evers, R, et al.
Publicado: (2000)

Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
por: Wang, Hai, et al.
Publicado: (2021)

The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
por: Ding, Pei-Rong, et al.
Publicado: (2011)

The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
por: Gao, Wei, et al.
Publicado: (2014)

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
por: Patel, Krupa J, et al.
Publicado: (2009)

Serum Amyloid P Is a Sialylated Glycoprotein Inhibitor of Influenza A Viruses
por: Job, Emma R., et al.
Publicado: (2013)

Using the Variable-Nearest Neighbor Method To Identify P-Glycoprotein Substrates and Inhibitors
por: Schyman, Patric, et al.
Publicado: (2016)

Computational Insights into Allosteric Conformational Modulation of P-Glycoprotein by Substrate and Inhibitor Binding
por: Xing, Juan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t6fdn5frj82roui6073f3jutop